Opinion|Videos|January 28, 2025
Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting
Panelists discuss how second-line treatment selection in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) requires careful consideration of prior therapy exposure, with noncovalent Bruton tyrosine kinase (BTK) inhibitors showing particular promise for patients with BTK resistance mutations while noting that matching-adjusted indirect comparisons (MAIC) analyses, though informative, must be interpreted cautiously in the absence of direct comparative trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Switching gears to the R/R CLL population, what is your general treatment approach in the second-line setting?
- How does prior first-line therapy influence your treatment decision?
- In what clinical scenarios may you consider a noncovalent BTK inhibitor for patients with R/R CLL?
- There have been multiple MAIC analyses reported out so far. What are your thoughts, and how do you interpret this data and apply it to real-life day to day practice without head-to-head randomized controlled trials?
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5